Press Release

16th September, 2026 The Corporate Relationship Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai 400 001. Mumbai 400 051. Scrip Code: 539523 Scrip Symbol: ALKEM Sub: Press Release – Alkem Laboratories Limited launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients Dear Sir(s)/ Madam, This is to inform you that Alkem Laboratories Limited (the “Company”) today announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial- onset seizures in adult patients. A press release in this regard is enclosed herewith. Request you to kindly take the same on record. Sincerely, For Alkem Laboratories Limited Manish Narang President – Legal, Company Secretary & Compliance Officer Press Release Alkem launches NeuCeno (cenobamate) for the treatment of partial-onset seizures in adult patients Mumbai, 16 September 2026: Alkem Laboratories Ltd. (BSE: 539523, NSE: ALKEM, “Alkem” and its subsidiaries) today announced the launch of NeuCeno (cenobamate), anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. Cenobamate, being launched for the first time in India, represents a significant advancement in the management of epilepsy. NeuCeno is a once daily oral therapy, and is available in 12.5 mg, 25 mg, 50 mg, 100 mg, 150 mg and 200 mg tablets. Epilepsy is a significant healthcare burden in India, with an estimated 9.4 million people living with the condition. Despite the availability of multiple anti-seizure medications, a significant proportion of patients continue to experience uncontrolled seizures, substantially affecting their independence, daily functioning and overall quality of life. NeuCeno (cenobamate) acts through a unique dual mechanism of action, selectively inhibiting the persistent sodium current that drives repetitive neuronal firing, while enhancing the brain's natural inhibitory signaling via positive modulation of GABA-A receptors. In randomized clinical studies of adults with uncontrolled focal seizures on existing anti-seizure medications, adjunctive cenobamate produced up to 78% reduction in seizure frequency, with up to 30% patients achieving seizure freedom during the maintenance phase. Commenting on the launch, Sandeep Singh, Managing Director, Alkem Laboratories Limited, said, “People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management. At Alkem, we believe patients deserve access to advanced treatment options that can help address unmet medical needs. With the launch of NeuCeno (cenobamate), we reaffirm our commitment to improving patient care by enabling access to an important therapeutic option and supporting healthcare professionals in making informed treatment decisions for adults living with partial-onset seizures.” Alkem remains committed to advancing high-quality, affordable medicines across key therapeutic areas and supporting better patient care in India. About Alkem: Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with a legacy of 50 years in providing high-quality medicines to patients. It is the sixth-largest pharmaceutical company in the Indian market with a dominant position in the therapy areas of anti-infectives, gastrointestinal, pain management drugs and supplements. It also has a growing portfolio of products in chronic therapies such as diabetes, neurology, cardiology, dermatology and urology. It has 20 state-of-the- art manufacturing facilities and cutting-edge research and development (R&D) centres across India and the US to develop and manufacture generic formulations, active pharmaceutical ingredients (APIs) and biosimilars. Apart from India, the company has a meaningful presence in the US, Latin America, Australia and several Asian countries. “Inspiring Healthier Lives” is at the core of the values and culture of the organisation and reinforces its steadfast commitment to global health improvement. For more information, please visit www.alkemlabs.com and follow us on LinkedIn, Instagram, Facebook. Contacts Media: Investors: Richa Sinari Dishant Doshi alkemcorpcomm@alkem.com dishant.doshi@alkem.com +91-9820184988 +91-8082638391